33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15823)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7078)
  4. Hematologic Malignancies, Division of (6211)
  5. Center for Hematologic Malignancies (6018)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4873)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15823)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7078)
  4. Hematologic Malignancies, Division of (6211)
  5. Center for Hematologic Malignancies (6018)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I/II study of GB1275, a first-in-class oral CD11b modulator, alone, and combined with pembrolizumab in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (KEYNOTE-A36)
    Meeting Abstract

    Rasco, D. W.; Bendell, J. C.; Wang-Gillam, A.; Park, W.; O'Reilly, E. M.; Zhou, L.; Galkin, A.; Carter, L. L.; Nickle, D.; Li, J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Clinical characteristics, genomic features, and recurrence risk of early-stage MET exon 14 mutant non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Recondo, G.; Guo, R.; Cravero, P.; Ricciuti, B.; Falcon, C.; Vokes, N.; Kris, M. G.; Leonardi, G. C.; Lamberti, G.; Nguyen, T.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A blood-based multi-mRNA liquid biopsy with > 90% accuracy for diagnosis and assessment of prostate cancers
    Meeting Abstract

    Rahbar, K.; Kidd, M. S.; Drozdov, I. A.; Kitz, A.; Malczewska, A.; Rajwa, P.; Boegemann, M.; Bernemann, C.; Bodei, L.; Modlin, I. M.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Nivolumab plus ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1
    Meeting Abstract

    Ramalingam, S. S.; Ciuleanu, T. E.; Pluzanski, A.; Lee, J. S.; Schenker, M.; Caro, R. B.; Lee, K. H.; Zurawski, B.; Audigier-Valette, C.; Provencio, M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase II study to evaluate the need for > two doses of nivolumab plus ipilimumab combination (combo) immunotherapy
    Meeting Abstract

    Postow, M. A.; Goldman, D. A.; Shoushtari, A. N.; Warner, A. B.; Callahan, M. K.; Momtaz, P.; Naito, E.; Eton, O.; Nair, S.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • High-dose osimertinib for CNS progression in EGFR+ non-small cell lung cancer (NSCLC): A multi-institutional experience
    Meeting Abstract

    Piper-Vallillo, A.; Rotow, J. K.; Aredo, J. V.; Shaverdashvili, K.; Luo, J.; Carlisle, J. W.; Husain, H.; Muzikansky, A.; Heist, R. S.; Rangachari, D.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Long-term survivors and gilteritinib safety beyond one year in FLT3-mutated R/R AML: ADMIRAL trial follow-up
    Meeting Abstract

    Perl, A. E.; Martinelli, G.; Neubauer, A.; Berman, E.; Baer, M. R.; Larson, R. A.; Fathi, A. T.; Yokoyama, H.; Hosono, N.; Hasabou, N.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Towards data-driven decision-making for breast cancer patients undergoing mastectomy and reconstruction: Prediction of individual patient-reported outcomes at two-year follow-up using machine learning
    Meeting Abstract

    Pfob, A.; Mehrara, B.; Nelson, J.; Wilkins, E. G.; Pusic, A.; Sidey-Gibbons, C.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Clinical, genetic, and pathologic determinants of prostate cancer brain metastasis
    Meeting Abstract

    Patel, M.; Wijetunga, N. A.; Lobaugh, S.; Zhang, Z.; McBride, S. M.; Chan, T. A. T.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Statistical machine learning model to predict Oncotype DX risk category in women over age 50
    Meeting Abstract

    Pawloski, K. R.; Gonen, M.; Wen, H. Y.; Tadros, A. B.; Abbate, K.; Thompson, D.; Morrow, M.; El-Tamer, M.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save